Anti-UBQLN4 Rabbit Polyclonal Antibody for WB, IHC-P, IF/ICC, ELISA - Q9NRR5

Core Product Specifications and Parameters

Biological Background: UBQLN4 Function and Localization

• UBQLN4 (Ubiquilin-4), also termed A1Up or CIP75, is a proteasomal targeting factor that mediates degradation of misfolded, mislocalized, or accumulated proteins. Related references: PMID:15280365, PMID:27113755, PMID:29666234

• Through its UBA domain, it binds polyubiquitin chains on substrates, while its ubiquitin-like (UBL) domain engages the proteasome, facilitating substrate delivery. Related references: PMID:15280365, PMID:27113755, PMID:30612738

• It is a critical DNA repair regulator: upon ATM-mediated phosphorylation, UBQLN4 is recruited to double-strand breaks, where it binds and removes ubiquitinated MRE11 for proteasomal degradation, suppressing homologous recombination and promoting NHEJ. Related references: PMID:30612738

• The protein specifically recognizes mislocalized transmembrane proteins and, in conjunction with DESI1/POST, exports ubiquitinated cargo from the nucleus to the cytoplasm for degradation. Related references: PMID:27113755, PMID:29666234

• UBQLN4 acts as an autophagy adaptor, recruiting UBQLN1 to autophagosomes and LC3, and potentially facilitating autophagosome-lysosome fusion. Related references: PMID:23459205

• Subcellularly, UBQLN4 is found in the nucleus, cytoplasm, chromosomes, endoplasmic reticulum, perinuclear region, and autophagic vesicles.

• It is most abundant in pancreas, kidney, skeletal muscle, heart, and brain; lower levels are detected in placenta, lung, and liver.

• Post-translational modifications include ATM-dependent phosphorylation and isopeptide bond formation; it is linked to neurodegenerative diseases and amyotrophic lateral sclerosis (ALS).

Experimental Guidance and Technical Tips

• The immunogen corresponds to the C‑terminal region (amino acids 366‑432). This region may be less conserved across species; verify sequence homology with your target species if intended for non‑human samples.

• As a polyclonal antibody, lot‑to‑lot consistency should be confirmed using a characterized positive control (e.g., HeLa or HEK293 cell lysate). A band at ~64 kDa is expected in WB.

• For IHC‑P and IF/ICC, consider antigen retrieval conditions and optimize the primary antibody dilution. Nuclear and cytoplasmic staining patterns are anticipated based on the protein’s localization; validate in known high‑expression tissues (e.g., pancreas, kidney).

• The antibody cross‑reacts with mouse and rat based on supplier data; if using these species, confirm specificity by siRNA knockdown or knockout model validation.

CamelBio: Your One‑Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research laboratories with reliable access to IVD raw materials, including antibodies targeting protein quality control, DNA repair, and neurodegeneration pathways. For UBQLN4-related studies, we offer validated antibody pairs, optimized monoclonal and polyclonal antibodies, and bulk ancillary reagents to support assay development. As a one‑stop sourcing partner, we also assist in procuring rare‑target raw materials, helping streamline your workflow from concept to clinic.